Obinutuzumab/chlorambucil gives OS benefit over rituximab in frontline CLL
The CAR T-cell therapy race
Supporting young hematology researchers: training programs offered by EHA and ASH
Using computational algorithms to predict the response of MDS patients to hypomethylating agents
What impact do side effects have on elderly chronic myeloid leukemia (CML) patients?